Danaher (NYSE:DHR) Releases Earnings Results, Beats Expectations By $0.14 EPS

Danaher (NYSE:DHR) posted its quarterly earnings data on Tuesday. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14, Briefing.com reports. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the company posted $2.02 earnings per share. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year.

Danaher Stock Performance

Shares of DHR opened at $250.00 on Friday. Danaher has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a 50 day moving average price of $270.43 and a two-hundred day moving average price of $260.43. The firm has a market capitalization of $185.17 billion, a P/E ratio of 42.01, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s payout ratio is 18.31%.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the transaction, the director now directly owns 41,149 shares in the company, valued at $11,501,145.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,059 shares of company stock valued at $8,400,897 over the last 90 days. Insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. Leerink Partners upped their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. KeyCorp raised their target price on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday. Stifel Nicolaus lifted their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday. Royal Bank of Canada cut their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Robert W. Baird reduced their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $287.28.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.